Axa increased its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 26.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 412,845 shares of the medical equipment provider’s stock after purchasing an additional 85,861 shares during the period. Axa owned 0.20% of Zimmer Biomet worth $48,340,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. CWA Asset Management Group LLC boosted its stake in Zimmer Biomet by 1.8% in the second quarter. CWA Asset Management Group LLC now owns 1,952 shares of the medical equipment provider’s stock valued at $251,000 after acquiring an additional 34 shares during the period. Advisory Services Network LLC boosted its stake in Zimmer Biomet by 1.0% in the second quarter. Advisory Services Network LLC now owns 3,690 shares of the medical equipment provider’s stock valued at $474,000 after acquiring an additional 37 shares during the period. Armor Investment Advisors LLC boosted its stake in Zimmer Biomet by 2.0% in the second quarter. Armor Investment Advisors LLC now owns 2,600 shares of the medical equipment provider’s stock valued at $334,000 after acquiring an additional 50 shares during the period. Geneva Advisors LLC boosted its stake in Zimmer Biomet by 2.7% in the second quarter. Geneva Advisors LLC now owns 2,107 shares of the medical equipment provider’s stock valued at $271,000 after acquiring an additional 55 shares during the period. Finally, Sandy Spring Bank boosted its stake in Zimmer Biomet by 5.4% in the second quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after acquiring an additional 66 shares during the period. Institutional investors and hedge funds own 86.24% of the company’s stock.

A number of equities analysts have commented on the company. BMO Capital Markets restated a “buy” rating and issued a $142.00 target price on shares of Zimmer Biomet in a research note on Tuesday. TheStreet downgraded Zimmer Biomet from a “b-” rating to a “c+” rating in a research report on Friday, November 24th. Zacks Investment Research downgraded Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, November 20th. Deutsche Bank upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price objective for the company in a research report on Tuesday, November 14th. Finally, Edward Jones upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Thursday, November 9th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $134.05.

Shares of Zimmer Biomet Holdings Inc (NYSE ZBH) traded up $2.42 during trading hours on Friday, reaching $115.24. 2,158,057 shares of the company’s stock traded hands, compared to its average volume of 1,250,446. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. Zimmer Biomet Holdings Inc has a 52 week low of $100.87 and a 52 week high of $133.49. The firm has a market cap of $22,839.17, a P/E ratio of 13.98, a P/E/G ratio of 1.75 and a beta of 1.15.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The company’s revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.79 earnings per share. analysts expect that Zimmer Biomet Holdings Inc will post 8.03 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/16/axa-boosts-position-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related stocks with our FREE daily email newsletter.